Oncolytics Biotech Inc. (ONCY)

Market Cap	85.89M
Revenue (ttm)	n/a
Net Income (ttm)	-22.30M
Shares Out	100.36M
EPS (ttm)	-0.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	516,791
Open	0.8300
Previous Close	0.8676
Day's Range	0.8300 - 0.8749
52-Week Range	0.3258 - 1.5300
Beta	1.48
Analysts	Strong Buy
Price Target	4.33 (+401.16%)
Earnings Date	Aug 8, 2025

About ONCY

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 8, 1999
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: ONCY
• Website: https://oncolyticsbiotech.com

Financial Performance

Financial numbers in CAD

Analyst Summary

According to 4 analysts, the average rating for ONCY stock is "Strong Buy." The 12-month stock price target is $4.33, which is an increase of 401.16% from the latest price.

Price Target

$4.33

(401.16% upside)

Analyst Consensus: Strong Buy